58.52

1.74% 1.0437

Travere Therapeutics Inc (TVTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TVTX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$57.48

Aprire:

$57.79

Volume 24 ore:

798.62K

Relative Volume:

0.32

Capitalizzazione di mercato:

$5.44B

Reddito:

$536.20M

Utile/perdita netta:

$-45.64M

Rapporto P/E:

-109.43

EPS:

-0.5348

Flusso di cassa netto:

$-28.94M

1 W Prestazione:

+2.94%

1M Prestazione:

+27.66%

6M Prestazione:

+61.19%

1 anno Prestazione:

+300.41%

Intervallo 1D:

$56.45

$58.79

Intervallo di 1 settimana:

$54.87

$58.79

Portata 52W:

$14.69

$60.10

Travere Therapeutics Inc Stock (TVTX) Company Profile

Nome

Travere Therapeutics Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

888-969-7879

Indirizzo

3611 VALLEY CENTRE DR, SAN DIEGO

Dipendente

497

Cinguettio

Prossima data di guadagno

2026-08-05

Ultimi documenti SEC

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TVTX Travere Therapeutics Inc	58.48	5.35B	536.20M	-45.64M	-28.94M	-0.5348
VRTX Vertex Pharmaceuticals Inc	522.00	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.79	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.13	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	319.99	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.13	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Aggiornamento	Piper Sandler	Neutral → Overweight
2025-10-31	Reiterato	Citigroup	Buy
2025-06-11	Reiterato	Citigroup	Buy
2025-06-11	Ripresa	H.C. Wainwright	Buy
2025-01-10	Iniziato	Cantor Fitzgerald	Overweight
2024-10-21	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-09-09	Aggiornamento	Guggenheim	Neutral → Buy
2024-03-27	Downgrade	Guggenheim	Buy → Neutral
2023-12-05	Aggiornamento	Citigroup	Neutral → Buy
2023-11-20	Iniziato	Citigroup	Neutral
2023-09-22	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-09-21	Downgrade	William Blair	Outperform → Mkt Perform
2023-09-06	Ripresa	Evercore ISI	Outperform
2023-07-21	Iniziato	JP Morgan	Overweight
2023-06-07	Ripresa	Piper Sandler	Neutral
2023-05-22	Iniziato	TD Cowen	Outperform
2023-05-05	Aggiornamento	Bryan Garnier	Sell → Neutral
2023-03-01	Iniziato	Guggenheim	Buy
2023-02-21	Aggiornamento	Wedbush	Neutral → Outperform
2022-12-14	Iniziato	Stifel	Hold
2022-12-05	Iniziato	Wells Fargo	Overweight
2022-09-21	Iniziato	Bryan Garnier	Sell
2022-07-14	Ripresa	Canaccord Genuity	Buy
2022-03-31	Iniziato	Piper Sandler	Overweight
2022-02-28	Iniziato	H.C. Wainwright	Buy
2021-05-26	Downgrade	Wedbush	Outperform → Neutral

Mostra tutto

Travere Therapeutics Inc Borsa (TVTX) Ultime notizie

10:42 AM

Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st

10:42 AM

07:09 AM

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - The Manila Times

07:09 AM

Jul 06, 2026

Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits

Jul 06, 2026

Jul 03, 2026

Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha

Jul 03, 2026

Jul 02, 2026

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits

Jul 02, 2026

Jun 30, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review

Jun 30, 2026

Jun 29, 2026

Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Understanding Momentum Shifts in (TVTX) - Stock Traders Daily

Jun 29, 2026

Jun 28, 2026

Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits

Jun 28, 2026

Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView

Jun 28, 2026

Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView

Jun 28, 2026

Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView

Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review

Jun 27, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review

Jun 27, 2026

Price to sales forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView

Jun 27, 2026

Jun 26, 2026

Travere Therapeutics stock hits 52-week high at 56.9 USD By Investing.com - Investing.com Australia

Jun 24, 2026

Travere Therapeutics stock hits 52-week high at 56.9 USD - Investing.com

Jun 24, 2026